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Abstract
Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney. The role of the von-Hippel-Lindeau
(VHL) tumour suppressor gene is well established in RCC with a loss of VHL protein leading to accumulated
hypoxia-induced factor (HIF) and the subsequent transcriptional activation of multiple downstream targets.
Recently, microRNAs (miRNAs) have been shown to be differentially expressed in RCC and their role in RCC patho-
genesis is emerging. This month, in BMC Medicine, Gleadle and colleagues show that certain miRNAs are regulated
by VHL in either a hypoxia-inducible factor (HIF)-dependent or HIF-independent manner in RCC. They also show
that miRNA expression correlates with the survival of RCC patients.
In this commentary, we discuss the current understanding of the role of miRNAs in RCC and the different possible
scenarios of their involvement in RCC pathogenesis. We also address their clinical significance as tumour markers,
together with the potential use of miRNAs as therapeutic targets. Finally, we discuss some of the challenges that
face the fast-evolving field of miRNAs, including the identification and validation of miRNA targets and the difficul-
ties associated with establishing a link between miRNA expression and biological effects. A more thorough under-
standing of the biological nature of miRNAs and careful experimental planning will help us to reveal the complex
role that miRNAs play in RCC pathogenesis.
See research article: http://www.biomedcentral.com/1741-7015/8/64
Introduction
This month, in BMC Medicine, Gleadle and colleagues
show, for the first time, the effect of the von-Hippel-
Lindeau (VHL) tumour suppressor gene on microRNA
(miRNA) expression in renal cell carcinoma (RCC) [1].
Their elegant work opens up a new dimension in the
investigation of the role of miRNAs in the pathogenesis
of RCC. It also highlights the potential challenges that
need to be addressed in order to allow a better under-
standing of the complex relationship between miRNAs
and cancer.
The VHL protein, which is defective in the majority of
patients with RCC, plays a well characterized role in the
pathogenesis of kidney cancer. Defective VHL leads to
an accumulation of the hypoxia-inducible factor (HIF)
and the activation of the hypoxic pathway of gene
expression [2]. Anaerobic respiration seen in renal (and
other) tumours can, therefore, be affected by the dysre-
gulation of the VHL pathway. More recently, it has been
shown that VHL has a number of other important func-
tions that are HIF-independent [3]. The paper by Neal
et al. identified a number of significantly dysregulated
VHL-dependant miRNAs. Interestingly, whereas some of
these miRNAs had altered expression as a consequence
of HIF upregulation as previously documented in the lit-
erature, other miRNAs were dysregulated in a HIF-
independent manner.
miRNAs are short non-coding, single-stranded RNAs
that function by regulating protein translation and mes-
senger RNA (mRNA) degradation of their target genes
[4]. They have been shown to be involved in a number
of critical biological processes, including cell develop-
ment, differentiation and apoptosis [5,6]. It is estimated
that about one-third of all human mRNAs are regulated
by miRNAs [7]. Several independent studies have shown
a strong link between dysregulated miRNAs and cancer,
including breast, prostate, lung and kidney cancers
[8-10]. Studies have shown that miRNAs affect the well-
known pathways involved in tumorigenesis, including
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angiogenesis and others [11].
Discussion
As we proceed into more in-depth analyses of the role
of miRNAs in cancer, it is now obvious that the relation
of miRNAs with cancer is more complex than initially
thought [11]. As shown in Figure 1, miRNA dysregula-
tion can be either a cause or an effect of carcinogenesis.
miRNAs can have oncogenic or tumour suppressor
effects by inhibiting the protein production of their
tumour suppressor or oncogenic targets, respectively.
T oa d dm o r ec o m p l e x i t yt ot h i si s s u e ,s o m em i R N A s
have been shown to be downstream targets of oncogenic
or tumour suppressor genes, such as p53 [12]. More-
over, it has been recently proposed that some miRNAs
m a yb eap a r to ft h ed e f e n c em e c h a n i s mo ft h eb o d y ’s
fight against carcinogenesis [13].
Evidence of the involvement of miRNAs in RCC
pathogenesis is emerging. Recent studies have documen-
ted miRNA dysregulation in RCC compared to normal
kidney tissue [10,14]. miRNAs can contribute to RCC
pathogenesis at different levels. Some miRNAs have
been shown to have an oncogenic effect on RCC [15].
T h ec u r r e n ts t u d yb yN e a let al. showed that miRNA
expression can be VHL-dependant.
It has been shown that several miRNAs are down-
stream effector molecules of the HIF-induced hypoxia
response. miR-210 increases under hypoxic conditions
and can target the iron-sulphur cluster protein (ISCU)
which is involved in the mitochondrial electron trans-
port chain, suggesting a potential mechanism for regu-
lating anaerobic respiration in tumours [1,16,17]. Other
miRNAs including miR-199a-5p and miR-135a [18] and
miR-449a/b [19] have also been shown to be regulated
by hypoxia.
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Figure 1 The complex involvement of microRNAs (miRNAs) in tumourigenesis. (A) Dysregulated miRNAs can have an oncogenic or tumour
suppressor effect by inhibiting the protein production of their tumour suppressor or oncogenic targets, respectively. (B) Some miRNAs can be
downstream targets of oncogenic of tumour suppressor genes, leading to their subsequent dysregulation and contribution to malignancy. (C)
miRNA dysregulation can also be due to defective processing, mutations or epigenetic aberrations. TSG: tumour suppressor genes
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hypoxia pathway, miRNAs can directly affect tumour
proliferation through mechanisms that are yet to be
identified. As shown in the current study, miRNAs,
including let-7i, miR-31, miR-21 and members of the
miR-17-92 cluster, may also be involved in non-HIF
mediated pathways in RCC [1]. The miR-17-92 cluster
has been shown to act as an oncogene in many different
cancers. Members of this cluster have been shown to be
involved in the regulation of MYC-induced cell prolif-
eration by targeting E2F1 expression. miRNAs can
directly control VHL, HIF, vascular endothelial growth
factor receptor (VEGFR) and other key molecules in
RCC pathogenesis [8,10,11]. Lastly, the regulation of
miRNA expression in RCC is complex, involving several
mechanisms such as mutations, epigenetic changes,
chromosomal aberrations and defective processing. We
have recently shown that chromosomal aberrations in
RCC (gain or loss) are responsible, at least in part, for
controlling miRNA expression [8, 10, Youssef Y, White
N M ,G r i g u l lJ ,K r i z o v aA ,S a m yC ,M e j i a - G u e r r e r oS ,
Evans A, Jewett M, Yousef GM: MiRNA profiling in kid-
ney cancer subtypes: accurate molecular classification
and correlation with cytogenetic and mRNA data identi-
fies unique and shared biological pathway, Submitted].
On the clinical frontier, miRNA expression levels can
serve as diagnostic, prognostic and predictive tumour
markers [14,20-22]. In the study by Neal et al.[ 1 ] ,t h e
expression of miR-210 was shown to be a prognostic
marker as its expression correlated with patient survival.
Other studies have also shown a correlation between
other miRNAs and the different subtypes of RCC [23]
and tumour size [10]. Previous studies in multiple can-
cers have provided the rationale of using miRNAs as
potential cancer therapeutic targets [24-26]. This is also
applicable to RCC, as recent reports have suggested that
key molecules in kidney cancer pathogenesis represent
potential targets of miRNAs [8,10]. miRNA gene therapy
is particularly interesting because it offers the appeal of
targeting multiple genes simultaneously. This is espe-
cially exciting as RCC is notorious for being resistant to
therapy, especially in the metastatic stage.
The accompanying paper raises interesting technical
challenges. The first of these is the identification and
validation of miRNA targets. Currently, there are
numerous target prediction programs but all of them
lack sensitivity and specificity. The experimental valida-
tion of miRNA targets is an essential step towards a bet-
ter understanding of the role of miRNAs in cancer
pathogenesis. This is not, however, a simple process
considering that target prediction is based on (1) partial
complementarity with target mRNAs, (2) a single
miRNA can target a large number of genes and (3) the
fact that the same mRNA can be targeted by multiple
miRNAs [21,27]. Establishing a high-throughput techni-
que for the global validation of miRNA targets will need
to be the corner-stone of miRNA research.
Although miRNA microarrays are a great initial tool
for the discovery phase because they are operation-
dependent their results are not consistent, they need to
be validated by a gold standard technique (for example,
the use of quantitative real time PCR with gene-specific
primers) as shown in the paper by Neal et al.A l s o ,
since an individual miRNA can have multiple targets,
special care must be taken in the experimental design
and the appropriate controls must be included. These
include the co-transfection of the miRNA and its
antagonist (the antagomir) and a control, or ‘scramble’,
miRNA. The latter can be somewhat problematical as,
given the fact that miRNA interaction with the target
relies on imperfect complementarity, it may give unex-
pected results. In this case, site-directed mutagenesis of
the miRNA sequence may be preferred.
Another interesting challenge for miRNA research is
the establishment of a direct relationship between
miRNA dysregulation, target dysregulation and the end-
point biological effect. This can be tricky as miRNAs
can have an indirect effect on certain biological pro-
cesses via alternate targets. Also, rather than being
directly effected by the miRNA, the targeted gene may
be a downstream target of these affected processes.
Concurrent to developments in the miRNA field,
improvements are required in animal models of diseases,
in order to thoroughly test the effect of potential
miRNA therapeutics.
Conclusion
Current evidence shows that miRNAs will have a signifi-
cant impact on our understanding of the pathogenesis of
RCC. More studies are required in order to accurately
identify the mechanisms by which miRNAs affect RCC.
Moreover, miRNAs present new potential tumour bio-
markers that will improve our diagnostic, prognostic
and predictive abilities and, consequently, cancer patient
management. Since the discovery that miRNAs can have
direct biological effects on cancer, there has been much
interest in developing novel miRNA-based cancer thera-
pies. The development of a useful miRNA therapy has
the capability to revolutionize personalized cancer ther-
apy. Although many challenges exist in the field of
miRNA research, continuing technological advances will
help to overcome these challenges and enable us to
understand the effect of miRNAs on RCC - and other
tumour - pathogenesis.
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